Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerstein

Showing results (71-80 of 1,912) with videos related to

Pageof 192
Sort By:
Nature Reviews. Endocrinology|May 16, 2009
Is it possible to reduce cardiovascular risk with glucose-lowering approaches?Hertzel C Gerstein
Diabetes Care|July 27, 2016
Making a Difference With Diabetes Research and CareHertzel C Gerstein
The Lancet. Diabetes & Endocrinology|June 20, 2020
Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trialsHertzel C Gerstein
Journal of Neuroscience Methods|October 21, 2000
Cross-correlation measures of unresolved multi-neuron recordingsG L Gerstein
Addiction (Abingdon, England)|January 1, 1993
Heart and heedD R Gerstein
ACP Journal Club|November 5, 2003
Enalapril reduced the risk for developing new-onset diabetes in left ventricular dysfunctionHertzel C Gerstein
Advances in Experimental Medicine and Biology|March 20, 2002
The plasma glucose level--a continuous risk factor for vascular disease in both diabetic and non-diabetic peopleH C Gerstein
Revista Portuguesa De Cardiologia|March 16, 2019
The PARADIGM-HF population may be very different from real-world heart failure patientsWalter Calderón-Gerstein
Diabetes Research and Clinical Practice|September 18, 1998
Dysglycaemia: a cardiovascular risk factorH C Gerstein
Acta Neurobiologiae Experimentalis|January 1, 1974
Plasticity in small neuronal assembliesG L Gerstein
Pageof 192

Showing results (71-80 of 1,912) with videos related to

Sort By:
Pageof 192
Nature Reviews. Endocrinology|May 16, 2009
Is it possible to reduce cardiovascular risk with glucose-lowering approaches?Hertzel C Gerstein
Diabetes Care|July 27, 2016
Making a Difference With Diabetes Research and CareHertzel C Gerstein
The Lancet. Diabetes & Endocrinology|June 20, 2020
Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trialsHertzel C Gerstein
Journal of Neuroscience Methods|October 21, 2000
Cross-correlation measures of unresolved multi-neuron recordingsG L Gerstein
Addiction (Abingdon, England)|January 1, 1993
Heart and heedD R Gerstein
ACP Journal Club|November 5, 2003
Enalapril reduced the risk for developing new-onset diabetes in left ventricular dysfunctionHertzel C Gerstein
Advances in Experimental Medicine and Biology|March 20, 2002
The plasma glucose level--a continuous risk factor for vascular disease in both diabetic and non-diabetic peopleH C Gerstein
Revista Portuguesa De Cardiologia|March 16, 2019
The PARADIGM-HF population may be very different from real-world heart failure patientsWalter Calderón-Gerstein
Diabetes Research and Clinical Practice|September 18, 1998
Dysglycaemia: a cardiovascular risk factorH C Gerstein
Acta Neurobiologiae Experimentalis|January 1, 1974
Plasticity in small neuronal assembliesG L Gerstein
Pageof 192